Company Analysis
Sign in

AC Immune SA (ACIU)

Nasdaq: ACIU · Pharmaceutical Preparations · 1015 Lausanne, CH · filing with the SEC since 2015
Full chart Alerts Compare
Grade4.4
◀ Past 5.3● Present 4.1▶ Future 3.9
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

64 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AC Immune SA’s names, not what it holds today.

Patents granted
64
64 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 2 in 2024 and 6 in 2023
Applications published
125
14 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals15
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
AC Immune SA its own name
CH, as the owner printed on each patent
64 granted
58 published
AC Immune SA its own name
named as the applicant on its applications, in CH
0 granted
67 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,319Anti-tau antibodies and methods of usePharmaceuticalsAC Immune SA
Jun 10, 202512,324,855Method of safe administration of phosphorylated Tau peptide vaccinePharmaceuticalsAC Immune SA
May 6, 202512,290,553Method for vaccination against a self-antigen in a human patientPharmaceuticalsAC Immune SA
Jan 21, 202512,202,840Compounds for the treatment or alleviation of disorders associated with Tau aggregatesOrganic fine chemistryAC Immune SA
Jun 11, 202412,005,102Anti-abeta therapeutic vaccinesPharmaceuticalsAC Immune SA
Apr 16, 202411,958,889Compositions of phosphorylated tau peptides and uses thereofPharmaceuticalsAC Immune SA
Nov 14, 202311,814,378Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregatesPharmaceuticalsAC Immune SA
Jun 27, 202311,684,625Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregatesPharmaceuticalsAC Immune SA
Jun 27, 202311,684,576Method of safe administration of phosphorylated tau peptide vaccinePharmaceuticalsAC Immune SA
Apr 11, 202311,623,931Bicyclic compounds for diagnosis and therapyOrganic fine chemistryAC Immune SA
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 6, 20252025/0340623Novel Molecules for Therapy and DiagnosisPharmaceuticalsAC Immune SA
Oct 23, 20252025/0326806Compositions of Phosphorylated Tau Peptides and Uses ThereofPharmaceuticalsAC Immune SA
Oct 16, 20252025/0320284Novel Molecules for Therapy and DiagnosisPharmaceuticalsAC Immune SA
Oct 16, 20252025/0320283Antibodies Binding to Alpha-Synuclein for Therapy and DiagnosisBiotechnologyAC Immune SA
Sep 4, 20252025/0275920Method of Safe Administration of Phosphorylated TAU Peptide VaccinePharmaceuticalsAC Immune SA
May 15, 20252025/0152684Anti-Alpha-Synuclein Therapeutic VaccinesPharmaceuticalsAC Immune SA
May 8, 20252025/0145695Humanized Anti-TDP-43 Binding Molecules and Uses ThereofPharmaceuticalsAC Immune SA
May 8, 20252025/0144212LIPOSOMES CONTAINING PHOSPHORYLATED TAU PEPTIDES FOR INDUCING SUSTAINED IMMUNE RESPONSESPharmaceuticalsAC Immune SA
May 1, 20252025/0134973Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune ResponsesPharmaceuticalsAC Immune SA
Apr 24, 20252025/0127867METHOD OF TREATING PRECLINICIAL ALZHEIMER'S DISEASEPharmaceuticalsAC Immune SA
What it applied for, 2024 to 2025: Pharmaceuticals 15 · Organic fine chemistry 5 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ACIU · research, not advice